vs
CSG SYSTEMS INTERNATIONAL INC（CSGS）とLivaNova PLC（LIVN）の財務データ比較。上の社名をクリックして会社を切り替えられます
LivaNova PLCの直近四半期売上が大きい（$360.9M vs $323.1M、CSG SYSTEMS INTERNATIONAL INCの約1.1倍）。LivaNova PLCの純利益率が高く（8.6% vs 2.2%、差は6.4%）。LivaNova PLCの前年同期比売上増加率が高い（12.1% vs 2.0%）。CSG SYSTEMS INTERNATIONAL INCの直近四半期フリーキャッシュフローが多い（$55.8M vs $50.2M）。過去8四半期でLivaNova PLCの売上複合成長率が高い（10.6% vs 4.6%）
中国南玻集団股フン有限公司は中国最大級の建築用ガラスメーカーで、浮きガラス、建築用ガラス、ディスプレイ用ガラス、自動車用ガラス、コーティングガラス、鏡、カラーフィルターガラス、太陽光発電用ガラス、省エネガラスなど多種多様なガラス製品の製造・販売を手がけています。
LivaNova PLCは医療機器メーカーで、イギリスに本社を置いています。心臓外科手術用機器と神経調整用機器の開発を主な事業とし、2015年に米国のサイバロニクス社とイタリアのソリン社が27億米ドルで合併して設立されました。現在はNASDAQに上場し、証券コードはLIVNです。
CSGS vs LIVN — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $323.1M | $360.9M |
| 純利益 | $7.0M | $30.9M |
| 粗利率 | 50.0% | 65.2% |
| 営業利益率 | 9.0% | 11.8% |
| 純利益率 | 2.2% | 8.6% |
| 売上前年比 | 2.0% | 12.1% |
| 純利益前年比 | -79.7% | -44.7% |
| EPS（希薄化後） | $0.24 | $0.57 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $323.1M | $360.9M | ||
| Q3 25 | $303.6M | $357.8M | ||
| Q2 25 | $297.1M | $352.5M | ||
| Q1 25 | $299.5M | $316.9M | ||
| Q4 24 | $316.7M | $321.8M | ||
| Q3 24 | $295.1M | $318.1M | ||
| Q2 24 | $290.3M | $318.6M | ||
| Q1 24 | $295.1M | $294.9M |
| Q4 25 | $7.0M | $30.9M | ||
| Q3 25 | $20.5M | $26.8M | ||
| Q2 25 | $12.3M | $27.2M | ||
| Q1 25 | $16.1M | $-327.3M | ||
| Q4 24 | $34.5M | $55.9M | ||
| Q3 24 | $19.1M | $33.0M | ||
| Q2 24 | $13.8M | $16.3M | ||
| Q1 24 | $19.5M | $-41.9M |
| Q4 25 | 50.0% | 65.2% | ||
| Q3 25 | 48.1% | 68.4% | ||
| Q2 25 | 49.5% | 67.8% | ||
| Q1 25 | 48.4% | 69.7% | ||
| Q4 24 | 51.3% | 68.2% | ||
| Q3 24 | 49.4% | 70.8% | ||
| Q2 24 | 47.3% | 68.7% | ||
| Q1 24 | 46.5% | 70.3% |
| Q4 25 | 9.0% | 11.8% | ||
| Q3 25 | 10.0% | 15.1% | ||
| Q2 25 | 10.0% | 15.4% | ||
| Q1 25 | 9.8% | 15.3% | ||
| Q4 24 | 13.4% | 11.5% | ||
| Q3 24 | 10.8% | 11.2% | ||
| Q2 24 | 8.8% | 12.6% | ||
| Q1 24 | 10.8% | 5.5% |
| Q4 25 | 2.2% | 8.6% | ||
| Q3 25 | 6.7% | 7.5% | ||
| Q2 25 | 4.1% | 7.7% | ||
| Q1 25 | 5.4% | -103.3% | ||
| Q4 24 | 10.9% | 17.4% | ||
| Q3 24 | 6.5% | 10.4% | ||
| Q2 24 | 4.8% | 5.1% | ||
| Q1 24 | 6.6% | -14.2% |
| Q4 25 | $0.24 | $0.57 | ||
| Q3 25 | $0.73 | $0.49 | ||
| Q2 25 | $0.44 | $0.50 | ||
| Q1 25 | $0.57 | $-6.01 | ||
| Q4 24 | $1.20 | $1.04 | ||
| Q3 24 | $0.67 | $0.60 | ||
| Q2 24 | $0.48 | $0.30 | ||
| Q1 24 | $0.68 | $-0.78 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $180.0M | $635.6M |
| 総負債低いほど良い | $539.5M | $376.1M |
| 株主資本純資産 | $283.7M | $1.2B |
| 総資産 | $1.5B | $2.6B |
| 負債/資本比率低いほどレバレッジが低い | 1.90× | 0.31× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $180.0M | $635.6M | ||
| Q3 25 | $158.4M | $646.1M | ||
| Q2 25 | $145.9M | $593.6M | ||
| Q1 25 | $136.0M | $738.4M | ||
| Q4 24 | $161.8M | $428.9M | ||
| Q3 24 | $118.4M | $346.4M | ||
| Q2 24 | $110.4M | $329.2M | ||
| Q1 24 | $120.8M | $309.2M |
| Q4 25 | $539.5M | $376.1M | ||
| Q3 25 | $538.6M | $434.5M | ||
| Q2 25 | $537.8M | $430.6M | ||
| Q1 25 | $537.6M | $628.2M | ||
| Q4 24 | $538.5M | $627.0M | ||
| Q3 24 | $539.5M | $625.5M | ||
| Q2 24 | $540.5M | $624.5M | ||
| Q1 24 | $541.5M | $623.8M |
| Q4 25 | $283.7M | $1.2B | ||
| Q3 25 | $289.5M | $1.2B | ||
| Q2 25 | $290.7M | $1.1B | ||
| Q1 25 | $283.1M | $1.0B | ||
| Q4 24 | $282.6M | $1.3B | ||
| Q3 24 | $288.4M | $1.3B | ||
| Q2 24 | $273.3M | $1.2B | ||
| Q1 24 | $269.3M | $1.2B |
| Q4 25 | $1.5B | $2.6B | ||
| Q3 25 | $1.5B | $2.6B | ||
| Q2 25 | $1.4B | $2.5B | ||
| Q1 25 | $1.4B | $2.6B | ||
| Q4 24 | $1.5B | $2.5B | ||
| Q3 24 | $1.4B | $2.5B | ||
| Q2 24 | $1.4B | $2.5B | ||
| Q1 24 | $1.3B | $2.5B |
| Q4 25 | 1.90× | 0.31× | ||
| Q3 25 | 1.86× | 0.38× | ||
| Q2 25 | 1.85× | 0.38× | ||
| Q1 25 | 1.90× | 0.61× | ||
| Q4 24 | 1.91× | 0.47× | ||
| Q3 24 | 1.87× | 0.48× | ||
| Q2 24 | 1.98× | 0.50× | ||
| Q1 24 | 2.01× | 0.51× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $59.2M | $82.4M |
| フリーキャッシュフロー営業CF - 設備投資 | $55.8M | $50.2M |
| FCFマージンFCF / 売上 | 17.3% | 13.9% |
| 設備投資強度設備投資 / 売上 | 1.1% | 8.9% |
| キャッシュ転換率営業CF / 純利益 | 8.46× | 2.67× |
| 直近12ヶ月FCF直近4四半期 | $141.4M | $173.3M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $59.2M | $82.4M | ||
| Q3 25 | $47.9M | $85.1M | ||
| Q2 25 | $37.3M | $62.9M | ||
| Q1 25 | $11.5M | $24.0M | ||
| Q4 24 | $82.5M | $78.7M | ||
| Q3 24 | $39.5M | $51.0M | ||
| Q2 24 | $43.1M | $43.4M | ||
| Q1 24 | $-29.4M | $10.0M |
| Q4 25 | $55.8M | $50.2M | ||
| Q3 25 | $43.9M | $62.2M | ||
| Q2 25 | $34.6M | $47.8M | ||
| Q1 25 | $7.1M | $13.2M | ||
| Q4 24 | $76.6M | $68.3M | ||
| Q3 24 | $32.0M | $32.8M | ||
| Q2 24 | $38.8M | $31.2M | ||
| Q1 24 | $-34.1M | $3.6M |
| Q4 25 | 17.3% | 13.9% | ||
| Q3 25 | 14.5% | 17.4% | ||
| Q2 25 | 11.6% | 13.6% | ||
| Q1 25 | 2.4% | 4.2% | ||
| Q4 24 | 24.2% | 21.2% | ||
| Q3 24 | 10.8% | 10.3% | ||
| Q2 24 | 13.4% | 9.8% | ||
| Q1 24 | -11.6% | 1.2% |
| Q4 25 | 1.1% | 8.9% | ||
| Q3 25 | 1.3% | 6.4% | ||
| Q2 25 | 0.9% | 4.3% | ||
| Q1 25 | 1.5% | 3.4% | ||
| Q4 24 | 1.9% | 3.2% | ||
| Q3 24 | 2.5% | 5.7% | ||
| Q2 24 | 1.5% | 3.8% | ||
| Q1 24 | 1.6% | 2.2% |
| Q4 25 | 8.46× | 2.67× | ||
| Q3 25 | 2.34× | 3.18× | ||
| Q2 25 | 3.04× | 2.32× | ||
| Q1 25 | 0.71× | — | ||
| Q4 24 | 2.39× | 1.41× | ||
| Q3 24 | 2.07× | 1.55× | ||
| Q2 24 | 3.12× | 2.65× | ||
| Q1 24 | -1.51× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
CSGS
| Software As A Service And Related Solutions | $287.2M | 89% |
| License And Service | $22.6M | 7% |
| Maintenance | $13.3M | 4% |
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
